A role of G-protein coupled receptor-mediated signal transduction on growth, invasion and antiapoptosis of human pancreatic cancer cells
G蛋白偶联受体介导的信号转导对人胰腺癌细胞生长、侵袭和抗凋亡的作用
基本信息
- 批准号:16591304
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2004
- 资助国家:日本
- 起止时间:2004 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Recently, angiotensin II (Ang II), trypsin and lysophosphatidic acid (LPA) has attracted considerable attention because activation of their specific G-protein-coupled receptors (AT1, PAR-2, and EDG-2,-4) can induce G protein-mediated signal transduction and is involved in a number of physiologic and pathologic processes such as inflammation and tumor progression. The purpose of this study was to investigate whether tumor-derived angiotensin II, trypsin and LPA plays an important role in the proliferation and survival of human pancreatic cancers through their specific G-protein-coupled receptors. As a result, all three pancreatic cancer cell lines (AsPC-1, BxPC-3, and Panc-1) studied, from well to poorly differentiated types, showed a moderate to strong expression of AT1, PAR-2 and EDG-2,-4 receptors. As to the signal transduction of pancreatic cancer cells, angiotensin II and trypsin stimulated the growth of pancreatic cancer cells even at the concentration of 100 nM or less through MAP kinase activation, and prevented cisplatin (CDDP)-induced apoptosis through NF-kB activation and the subsequent production of anti-apoptotic molecules, including Survivin and Bcl-XL. However, LPA did not stimulated the growth of pancreatic cancer cells at the concentration of less than 1 μM. In summary, it is suggested that not only tumor-derived angiotensin II but also tumor-derived trypsin must be a very potent mitogen and play a pivotal role in the growth and chemoresistance of AT1-positive and/or PAR-2 positive pancreatic cancer cells. Elucidation of the signal transduction machinery activated by tumor-derived angiotensin II and/or trypsin may provide insight into the molecular mechanisms underlying growth and chemoresistance of pancreatic cancers and ultimately lead to novel chemotherapies.
近年来,血管紧张素II(angiotensin II,Ang II)、胰蛋白酶和溶血磷脂酸(lysophosphatidic acid,LPA)等特异性G蛋白偶联受体(AT 1,PAR-2,EDG-2,-4)的激活,可诱导G蛋白介导的信号转导,参与炎症、肿瘤等多种生理病理过程,引起了人们的广泛关注。本研究的目的是探讨肿瘤源性血管紧张素II,胰蛋白酶和LPA是否通过其特异性G蛋白偶联受体在人胰腺癌的增殖和生存中起重要作用。结果,研究的所有三种胰腺癌细胞系(AsPC-1、BxPC-3和Panc-1),从分化良好到分化不良的类型,均显示出AT 1、PAR-2和EDG-2、-4受体的中度至强烈表达。至于胰腺癌细胞的信号传导,血管紧张素II和胰蛋白酶甚至在100 nM或更低的浓度下通过MAP激酶活化刺激胰腺癌细胞的生长,并通过NF-κ B活化和随后的抗凋亡分子(包括Survivin和Bcl-XL)的产生防止顺铂(CDDP)诱导的凋亡。LPA浓度低于1 μM时对胰腺癌细胞生长无明显刺激作用。总之,这表明,不仅肿瘤来源的血管紧张素II,而且肿瘤来源的胰蛋白酶必须是一个非常有效的促分裂剂,并在AT 1阳性和/或PAR-2阳性胰腺癌细胞的生长和耐药性中发挥关键作用。阐明由肿瘤源性血管紧张素II和/或胰蛋白酶激活的信号转导机制可能会深入了解胰腺癌生长和化疗耐药性的分子机制,并最终导致新的化疗。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type 1 receptor in human pancreatic cancer cells.
血管紧张素 II 通过人胰腺癌细胞中的血管紧张素 II 1 型受体激活 MAP 激酶和 NF-kappaB。
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Amaya K;Ohta T;et al.
- 通讯作者:et al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OHTA Tetsuo其他文献
OHTA Tetsuo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OHTA Tetsuo', 18)}}的其他基金
Development of new refractory cancer treatment by remodelinginduction of cancer stroma
通过癌基质重塑诱导开发新的难治性癌症治疗方法
- 批准号:
22591515 - 财政年份:2010
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthesis of α-Amino Acids via Phosphine-Catalyzed Three-Component Coupling Reactions
膦催化三组分偶联反应合成α-氨基酸
- 批准号:
14550812 - 财政年份:2002
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy for the therapy of pancreatic cancer by a specific ligand of peroxisome proliferator-activated receptor-gamma
过氧化物酶体增殖物激活受体-γ特异性配体治疗胰腺癌的新策略
- 批准号:
12671213 - 财政年份:2000
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Investigation on naphthylisoquinoline alkaloids as potential antiausterity chemotherapy for pancreatic cancer
萘基异喹啉生物碱作为胰腺癌潜在抗紧缩化疗的研究
- 批准号:
23K26797 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Proton radiation therapy combined with immunotherapy for enhancing antitumor immune responses in pancreatic cancer murine models.
质子放射治疗与免疫治疗相结合,增强胰腺癌小鼠模型的抗肿瘤免疫反应。
- 批准号:
24K10423 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Conditionally Activable Small Molecule Pro-Drug Conjugate for Targeted Treatment of Pancreatic Cancer
用于胰腺癌靶向治疗的条件激活小分子前药偶联物
- 批准号:
EP/Y036336/1 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Research Grant
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 2.24万 - 项目类别:
Developing a Curative Therapy for Cancer Stroma Alterations in Pancreatic Cancer and Other Intractable Solid Tumors
开发针对胰腺癌和其他难治性实体瘤的癌症基质改变的治疗方法
- 批准号:
23H02868 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional Analysis of Girdin in Anticancer Drug-Resistant Pancreatic Cancer and Its Application to Novel Therapeutic Agents
Girdin在抗癌药物耐药性胰腺癌中的功能分析及其在新型治疗药物中的应用
- 批准号:
23K08138 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Photoimmunotherapy for Novel Targets in Peritoneal metastasis of Pancreatic Cancer
光免疫疗法治疗胰腺癌腹膜转移的新靶点
- 批准号:
23K06753 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Nanobubbles for earlier pancreatic cancer detection
用于早期胰腺癌检测的纳米气泡
- 批准号:
2886053 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Studentship
Exploring the molecular function of HIKESHI in pancreatic cancer tumor development and response to thermal/chemotherapy.
探索 HIKESHI 在胰腺癌肿瘤发展和热/化疗反应中的分子功能。
- 批准号:
23K14610 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
New stool biomarker proteins for pancreatic cancer by the proteome analysis
通过蛋白质组分析发现胰腺癌的新粪便生物标志物蛋白
- 批准号:
23K14643 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists